Medullary thyroid carcinoma (MTC) is a malignant tumour of the calcitonin-secreting parafollicular C cells of the thyroid, and occurs sporadically or as a component of the multiple endocrine neoplasia (MEN) type 2/familial medullary thyroid carcinoma (FMTC) syndromes. In the present study, we investigated the frequency of mtDNA mutations in 26 MTC tumour specimens (13 sporadic and 13 familial MTC) and their matched normal tissues by sequencing the entire coding regions of mitochondrial genome. Nonsynonymous mutations were detected in 20 MTC samples (76.9%): nine out of 13 sporadic MTC (69.2%) and 11 out of 13 (84.6%) familial MTC/MEN2. Both transition and transversion types of mutations were found in the samples. Interestingly, 76.2% (16/21) of transversion mutations were found in FMTC/MEN2 patients, whereas 66.7% (12/18) of transition mutations were in sporadic MTC. Synonymous mutations were found in 12 MTC samples. In total, we identified 27 transversion mutations (21 nonsynonymous and six synonymous) in MTC. Of them, 22 (81.5%) were from FMTC/MEN2, and five (18.5%) were from sporadic MTC. The association of transversion mutation with familial MTC/MEN2 was statistically significant (P ¼ 0.0015, binomial test). Majority of the mutations were involved in the genes located in the complex I of the mitochondrial genome, and were often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. Mitochondrial respiratory function was also compromised in a TT cell line, which carries mtDNA mutation at nt 4917 and 11 720, and in peripheral lymphocytes of MTC patients with mtDNA mutations. These data suggest that mtDNA mutation may be involved in MTC tumourigenesis and progression. Given that mtDNA mutation spectra are different between sporadic and familial MTC, different mechanisms of oxidative DNA damage may occur in the disease process.
Introduction
Although thyroid carcinoma represents only 1% of all malignant diseases, it is the most common malignancy of the endocrine system, accounting for the majority of deaths from endocrine cancers (Mazzaferri, 1993; Farid et al., 1995) . Thyroid carcinomas are histologically classified as papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC), accounting for approximately 80, 15, 2, and 4% of all thyroid malignancies, respectively (Hundahl et al., 1998) . PTC, FTC, and ATC are derived from follicular thyroid epithelial cells, whereas MTC is derived from calcitoninsecreting parafollicullar C cells. MTC occurs in either a sporadic or a familial form (75-80 and 20-25% of cases, respectively) (Girelli et al., 1998; Massoll and Mazzaferri, 2004) , and is a consistent feature of multiple endocrine neoplasia MEN2A, MEN2B, and familial non-MEN MTC (FMTC). Germline mutation of the RET protooncogene is found in the majority of patients with MEN2 and FMTC, and is considered the primary genetic cause of the disease (Marsh et al., 1997) . RET somatic point mutations have also been reported in 40-50% of sporadic MTCs (Hansford and Mulligan, 2000; Elisei et al., 2004) . Successful treatment of MTC depends heavily on early diagnosis and treatment. The current clinical strategies in the diagnosis and management of hereditary MTC rely on the routine plasma calcitonin assay and genetic testing for RET proto-oncogene mutations (Massoll and Mazzaferri, 2004) . Plasma calcitonin assay is a sensitive and specific marker for the presence of MTC and provides an accurate estimate of tumour burden. Genetic testing for RET proto-oncogene mutations provides an accurate diagnosis of gene carriers in risky family members and offers the best chance of cure for MTC by prophylactic total thyroidectomy and lymphadenectomy (Massoll and Mazzaferri, 2004) . It is estimated that the probability is 0.18% for a first-degree relative to inherit mutant RET gene from an individual who has sporadic MTC without germline RET mutation (Massoll and Mazzaferri, 2004) .
Germline mutations in nuclear genes that encode mitochondrial enzymes have been implicated in hereditary neoplasias (Eng et al., 2003) . For example, germline heterozygous mutations in autosomally encoded mitochondrial enzyme fumarate hydratase are associated with hereditary predisposition to papillary renalcell carcinoma and leiomyomatosis (Tomlinson et al., 2002; Kiuru and Launonen, 2004) , whereas homozygous fumarate hydratase mutations cause neurodegeneration (Bourgeron et al., 1994) . Germline mutations in autosomally encoded mitochondrial enzyme succinate dehydrogenase (SDH) subunits SDHD, SDHC, and SDHB (mitochondrial respiratory chain complex II) are associated with hereditary predisposition to phaeochomocytoma and paraganglioma, both of which are arising from chromaffin cells derived from neural crest precursors (Astuti et al., 2001; Benn et al., 2003) . Although thyroid C-cells are derived from neural crest cells and both MTC and phaeochomocytoma are part of MEN2A, mtDNA mutation has not been reported in the literature. In the present study, we investigated 26 MTC specimens and one MTC cell line for mtDNA mutation by sequence analysis of the entire coding region of mtDNA.
Materials and methods
Thyroid tumour specimens and cell line All tumour tissues were obtained from paraffin blocks in the pathology archives. In all, 26 MTC specimens were studied: 13 unrelated familial MTC and 13 sporadic MTC. The matched normal tissues were obtained from peripheral lymphocytes (12 samples) or lymph nodes (14 samples) from paraffin blocks in the pathology archives. The lymph nodes were confirmed to be normal and free of cancer metastasis by a pathology examination.
A total of 119 population controls , from the same ethnic background as the disease patients, were included in this study to help determine whether mtDNA sequence variants found in these samples were mutation or polymorphism. The study was reviewed and approved by the Institutional Review Board.
The MTC cell line TT was purchased from the American Type Culture Collection (Manassas, VA, USA). This line was established from a 77-year-old Caucasian female. Cells were maintained in F12 medium (Life Technologies, Inc., Rockville, MD, USA) supplemented with 10% fetal calf serum, penicillin (100 IU/ml), and streptomycin (10 mg/ml) (Life Technologies, Inc.).
DNA extraction
Tumour DNA was extracted from paraffin-embedded tissues as described previously (Shi et al., 1991) , with some modifications. Briefly, 5 mM sections were deparaffinized with 400 ml xylene and washed twice with absolute ethanol. The tissues were mixed with 50 ml digestion buffer (100 mM Tris, 5 mM EDTA, pH 8.0) with 50 mg of proteinase-K. The mixture was incubated at 371C overnight, followed by phenol/chloroform extraction and ethanol precipitation. The resulting DNA was dissolved in 50 ml TE buffer (10 mM Tris, 0.5 mM EDTA, pH 8.0). In all, 2 ml of the DNA was used for polymerase chain reaction (PCR) amplification of mtDNA. DNA from blood samples was extracted by the standard proteinase-K treatment, followed by phenol/chloroform extraction as previously described (Shi et al., 1999) .
DNA amplification and sequence analysis of mitochondrial genes and RET proto-oncogene The entire coding region of mitochondrial genome from patient and controls was amplified in 24 separate PCRs using single-set cycling conditions as detailed elsewhere (Rieder et al., 1998) . Each successfully amplified fragment was directly sequenced using the BigDye Terminator V3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and samples were run on the ABI prism 3100 sequencer (Applied Biosystems). The sequencing data obtained were compared with the Cambridge reference sequence (http://www.mitomap. org/mitomap/mitoseq.html). All fragments were sequenced in both the forward and reverse directions, and this was repeated at least twice for confirmation of any detected variant. To determine novelty of sequence changes, we compared sequence results with those in the MITOMAP database (http:// www.mitomap.org/mitomap/mitoseq.html), Human Mitochondrial Genome Database (http://www.genpat.uu.se/ mtDB), and mitochondrial sequences available at the GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html). Those sequence variants (present in both tumour and matched normal samples) that resulted in the amino-acid change were not reported by others as a polymorphism, and those not found in the population controls were considered as germline mutations. The RET proto-oncogene exons 10, 11, 13, 14, 15, and 16 were also sequenced to detect oncogenic mutations in the MTC samples as described previously (Punales et al., 2003) .
Interspecies conservation analysis
The amino-acid sequences obtained here were compared with the published sequences (http://us.expasy.org) for human, rat, bovine, chicken, mouse, Drosophila, chimpanzee, ostrich, cat, dog, horse, whale, seal, and chloroplast. The sequence alignments were performed using BioEdit software available at http://www.mbio.ncsu.edu/BioEdit/bioedit.html.
Prediction of pathogenicity
Prediction of pathogenicity was assessed utilizing the PolyPhen (Polymorphism Phenotyping) database accessible at http:// tux.embl heidelberg.de/ramensky/polyphen.cgi. PolyPhen is a tool which predicts the possible impact of an amino-acid substitution on the three-dimensional structure and function of a human protein using physical and comparative considerations. PolyPhen will also determine interspecies conservation for the substituted amino acid by performing alignments around the amino-acid substitution with all available aminoacid sequences (Ramensky et al., 2002) .
Resazurin assay for mitochondria respiratory function
The resazurin assay for mitochondria respiratory function was described previously (Zhang et al., 2004; . Briefly, 200 ml (approximately 1 Â 10 5 cells) of lymphocyte suspension in RPMI isolated from peripheral blood by the Ficoll-Hypaque method or TT cell line in F12 medium was added in triplicate into a 96-well plate and incubated at 371C for 60 min. Resazurin (6 mM final concentration, Aldrich Chemical Company, Inc., Milwaukee, WI, USA) was then pipetted into the wells and the plate was incubated for an additional 4 h. Fluorescence intensity at 530 nm excitation and 590 nm emissions was measured after subtracting background measurements (only resazurin and media) by an LS55 Luminesence Spectrometer fitted with a micro-plate reader (Perkin-Elmer Instruments, Shelton, CT, USA). Mitochondrial respiratory activity from each patient was compared with the mean from 20 normal controls (20-45 years of age individuals without known mitochondrial disorders or cancer), and was expressed as the percentage of reduction of fluorescence intensity (mean7s.d.). The experiment was repeated at least three times.
Results
We sequenced the entire coding region of mtDNA from 26 MTC specimens and one MTC cell line. The clinical data and mtDNA sequence variants of these patients are shown in Table 1 . A high number of sequence variations were detected by comparing our sequence data with those recoded in the mitochondrial databank and other databases ( Figure 1 , Tables 2 and 3 ). In all, 41 nonsynonymous mtDNA sequence variants (resulted in amino-acid change, D-loop deletion was not counted) were detected: 39 in the primary tumours and two in the TT cell line (Tables 1 and 2 ). These sequence variants were not present in 119 normal population controls from the same ethnic background and matching age as the patients , and were therefore considered to be mutations. Figure 1 Detection of mtDNA mutations in MTC samples by sequencing analysis. The entire coding region of the mitochondrial genome for patients and controls was amplified in 24 separate PCRs using single-set cycling conditions. Each successfully amplified fragment was directly sequenced using the BigDye Terminator V3.1 Cycle Sequencing kit, and samples were run on the ABI prism 3100 sequencer. Shown here are four representative chromatograms demonstrating four different mtDNA sequence changes. Nucleotide changes are indicated at the top of each sequence chromatogram.
mtDNA mutation in medullary thyroid carcinoma KK Abu-Amero et al
In contrast to the somatic mtDNA mutations in papillary thyroid carcinoma that we and others reported earlier (Yeh et al., 2000; Maximo et al., 2002; AbuAmero et al., 2005) , we detected germline nonsynonymous mtDNA mutations in 20 (76.9%) of 26 MTC samples (mutations present in both MTC samples and their matched normal tissues): nine out of 13 were sporadic MTC (69.23%) and 11 out of 13 (84.6%) were FMTC/MEN2 (Table 1) . Transition mutations such as purin to purin or pyrimidine to pyrimidine (A:T>G:C or C:G>T:A) were found in 46.1% of base substitutions (18/39) and the remaining 53.9% were transversion base substitutions (purin to pyrimidine such as G:C>T:A or C:G, or A:T>T:A or C:G). Interestingly, 76.2% (16/21) of transversion base substitutions were found in FMTC/MEN2 patients, whereas only 5/21 (23.8%) were in sporadic MTC. In fact, all FMTC/ MEN2 patients had at least one transversion mutation. The G:C>T:A (8/21, 38.1%) or G:C>C:G (6/21, 28.6%) base substitution was the most common transversion, accounting for 66.7% of total transversions detected. The transition base substitutions were present in both FMTC/MEN2 (6/18, 33.33%) and sporadic (12/18, 66.67%) MTC. Prediction of pathogenicity assessed with the PolyPhen (Polymorphism Phenotyping) database (http://tux.embl heidelberg.de/ramensky/polyphen.cgi). 'Probably damaging' constitutes high confidence of affecting protein function. 'Possibly damaging' reflects a likelihood of affecting protein function or structure, while 'Benign' changes most likely lack phenotypic effect. 'Unknown' means that PolyPhen did not make a prediction due to the lack of data. mtDNA mutation in medullary thyroid carcinoma KK Abu-Amero et al Out of 20, 14 patients (70%) had multiple mutations. The mutations at nt 7640 and 8914 occurred more than once in MTC/MEN2 patients ( Table 1) . The noncoding mitochondrial D-loop region was also sequenced in 10 out of 26 MTC samples. We identified 1 bp deletion at nt 16 188 in patient 17, who had another nonsynonymous sequence mutation at nt 8914. Both transition base substitutions at nt 4917 (A:T>G:A, Asn>Asp in the ND2 gene) and transversional base substitutions at nt 11 720 (C:G>A:T, Leu>Ile in the ND4) were found in the TT cell line. Majority of the sequence variants (18/42, 42.9%) were involved in the genes located in the complex I region, 6/42 (14.3%) in complex III, 6/42 (14.3%) in complex IV, 7/42 (16.7%) in complex V of the mitochondrial genome, and were often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. The remaining sequence variants were in the transfer RNA and ribosomal RNA genes of the mitochondrial genome (Table 2 ). Since we found so many transversions relative to transition mutations in FMTC/MEN2, we compared them to all the cancer-related nonsynonymous mtDNA mutations collected in the MITOMAP database. Interestingly, among 48 different nonsynonymous mtDNA mutations in the MITOMAP database, majority of them (41/48, 85.4%) were transition mutations and the remaining 14.6% (7/48) were transversion mutations.
Next, we estimated the proportion of mutant vs wild-type mtDNA in the tumour and normal tissue from each patient. Significantly higher mutant copies were detected in tumours than normal tissues in four out of 15 heteroplasmy nonsynonymous mutations: C3484G, C6153A, T9259A, and C14630G. All of them were predicted to be 'damaging' mutations by PolyPhen program. Homoplasmic mtDNA mutations in tumour have been interpreted to reflect a replicative advantage for mutated mtDNA copies (Polyak et al., 1998; Fliss et al., 2000) . However, recent studies have shown that homoplasmic mtDNA mutations could be explained without selection and may be caused by random genetic drift or chance (Coller et al., 2001; Elson et al., 2001) .
We also detected 15 synonymous mtDNA sequence variants (did not alter the amino-acid sequence), seven were novel and eight were previously reported in the mitochondrial databank (http://www.mitomap.org). The distribution and spectra of these variants were quite similar to those found in the nonsynonymous sequence changes (Tables 2 and 3 ). The transversion variants were only found in FMTC/MEN2 and transition variants were mainly in sporadic MTC. Since these sequence variants were not present in the normal population controls, they might be silent mutations. In total, we identified 27 transversion mutations (21 nonsynonymous and six synonymous) in MTC. Of them, 22 (81.5%) were from FMTC/MEN2 and five (18.5%) from sporadic MTC. Coincidently, the same number of transition mutations (18 nonsynonymous and nine synonymous) was found in MTC (including TT cell line). Among them, eight (29.6%) were from FMTC/MEN2 and 19 (70.4%) from sporadic MTC. We combined all the mutations (nonsynonymous and synonymous) to perform statistical analysis to assess the association of mutation type with disease phenotype (sporadic or FMTC/MEN2). The association of mtDNA transversion mutation with FMTC/MEN2 was statistically significant (P ¼ 0.0015, binomial test). The association of sporadic MTC with transition mutations was, however, not statistically significant (P ¼ 0.0522, binomial test). These results suggest that different mitochondria oxidative damage and repair mechanisms are involved in the generation of mtDNA mutations in the sporadic and FMTC/MEN2.
To further investigate whether there is a defect in mitochondria respiratory function, we performed resazurin assay of MTC cell line TT and peripheral lymphocytes from four patients with MTC. Three of them were MEN2A (patient # 14, 18, and 25), and one of them was sporadic (patient # 10). Their clinical diagnosis, mtDNA mutation, and germline RET The above listed synonymous sequence variants were not detected in 119 normal population controls and 284 individuals with various mitochondrial disorders, all of whom are from the same ethnic background as our MTC patients. Novelty was established by comparison with those in the MitoMap database as described in the footnote of Table 2 . mtDNA mutation in medullary thyroid carcinoma KK Abu-Amero et al mutation are presented in Table 1 . The resazurin assay is based on the reduction of resazurin, a nontoxic nonfluorescent redox-active blue dye traditionally used for evaluating the quality of raw milk and semen, to pink and highly fluorescent resorufin by electrons generated during mitochondria oxidative phosphorylation. This conversion can be monitored by fluorimetric measurement. It is a simple and rapid method of measuring the overall oxidative activity in live cells. As shown in Figure 2 , the reduction rate of resazurin into resorufin was significantly reduced in TT cells and lymphocytes from patients with mtDNA mutations as compared to the controls (Po0.01, Student's t-test), indicating that respiratory activity of the cells was decreased possibly due to a defected oxidative phosphorylation machinery caused by a pathological mtDNA mutation.
Discussion
Heritable mutations in mitochondrial genes have been associated with several neurodegenerative disorders such as Leber hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), and Leigh syndrome (Chinnery and Schon, 2003) . We have sequenced 92% of the mitochondrial genome, the entire coding region of mtDNA, and identified frequent (20/26, 76.9%) germline mitochondria gene mutations in MTCs derived from thyroid parafollicullar C cells, which is in sharp contrast to the frequent somatic mitochondria mutations found in many types of cancer, including thyroid carcinoma of follicular origin (Polyak et al., 1998; Fliss et al., 2000; Yeh et al., 2000; Jones et al., 2001; Maximo et al., 2002; . Although there is no significant difference in the percentage of mtDNA mutations between sporadic (9/13, 69.2%) and FMTC/ MEN2 (11/13, 84.6%), there is a striking difference in the mutation patterns between sporadic and FMTC/ MEN2. In all, 76% (16/21) of transversion mutations were found in FMTC/MEN2 patients.
Human mtDNA is a multi-copy extra-chromosomal DNA, which is constantly exposed to a high steady-state level of reactive oxygen species (ROS) and free radicals. ROS are formed in all living organisms as a byproduct of normal metabolism (endogenous sources) and as a consequence of exposure to environmental compounds such as ultraviolet (UV) radiation (exogenous sources). Endogenous ROS are largely formed during oxidative phosphorylation in the mitochondria and, therefore, mtDNA is much more vulnerable to oxidative damage and mutation than is nuclear DNA. It is estimated that mtDNA mutational rate is at least 10 times higher than nuclear DNA (Polyak et al., 1998; Wallace, 1999) . Unlike previous reports of mainly transition mutations (G:C>A:T or T:A>C:G) in many types of sporadic cancers (Polyak et al., 1998; Fliss et al., 2000; Yeh et al., 2000; Jones et al., 2001; Maximo et al., 2002; AbuAmero et al., 2005) , we found transversion mutations in all 11 FMTC/MEN2 patients who had mtDNA mutations. Most of them are G:C>T:A or G:C>C:G. The guanine base (G) is highly susceptible to oxidative stress due to having the lowest oxidation potential of the four DNA nucleobases (Cooke et al., 2003) . Therefore, G:C>T:A or G:C>C:G transversion mutations frequently occur under oxidative conditions. The typical oxidative lesion of G is 8-oxo-7, 8-dihydro-guanine (8-oxoG) , which is responsible for G:C>T:A transversion mutations but not for G:C>C:G transversion. The 8-oxoG secondary oxidation products cyanuric acid, oxaluric acid, and oxazolone give exclusively G>T mutations, whereas guanidinohydantoin generates exclusively G:C>C:G mutations and the spiroiminodihydantoin diastereomers yield a mixture of G:C>C:G and G:C>T:A mutations (Neeley et al., 2004) . The G:C>C:G transversions can also be induced by 2-aminoimidazolone, resulting from further oxidation of 8-oxoG under specific oxidation conditions such as riboflavin photosensitization or UV irradiation (Kino and Sugiyama, 2001) .
Oxidative DNA base lesions, including 8-oxoG, are repaired primarily by the base excision repair (BER) pathway, with transcription-coupled repair (TCR) and mismatch repair (MMR) being important backup pathways for repair of transcribed strands and newly replicated strands, respectively (Stevnsner et al., 2002; Slupphaug et al., 2003) . Although mitochondria contain all the enzymes required for BER, these proteins are encoded in the nuclear genome and must be directed to mitochondria in order to act on mtDNA (LeDoux and Figure 2 Resazurin assay for mitochondria respiratory function. TT cell line and peripheral blood lymphocytes from four MTC patients (patient #10, 14, 18, and 25) with mtDNA mutations were analysed by resazurin assay for mitochondria respiratory function. The clinical diagnosis, mtDNA mutation, and germline RET mutation of these patients are presented in Table 1 . Peripheral blood lymphocytes from 20 normal persons were used as controls. 1 Â 10 5 cells in 200 ml were added in triplicate into a 96-well plate and incubated at 371C for 60 min. Resazurin (6 mM) was then pipetted into the wells and the plate was incubated for 4 h. Fluorescence intensity was measured after subtracting the background by a spectrofluorometer. Mitochondrial respiratory activity from each patient was compared with the mean from 20 normal controls and was expressed as percentage of reduction of fluorescence intensity (mean7s.d.). The experiment was repeated at least three times. mtDNA mutation in medullary thyroid carcinoma KK Abu-Amero et al Wilson 2001; Mandavilli et al., 2002) . Thus, the scope of DNA repair activities undertaken within mitochondria is determined by the set of nucleus-encoded DNA repair enzymes that are capable of being imported into the organelle (Bogenhagen et al., 2001) . The different mutation patterns (transition vs transversion) found in sporadic and FMTC/MEN2 suggest that distinct oxidative stress conditions and repair mechanism defects are involved in the disease process.
Patients with FMTC/MEN2 usually carry germline RET oncogene mutations, resulting in continuous activation of tyrosine kinase (Santoro et al., 2004) . Multiple signal transductional pathways have been identified to be mediated by RET tyrosine kinase, such as the RAS/extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and c-Jun-N-terminal kinase/ stress-activated protein kinase (JNK/SAPK) cascades (De Vita et al., 2000; Segouffin-Cariou and Billaud, 2000; Kurokawa et al., 2003) . Their downstream transcription factors NF-kB and AP-1 (c-jun and c-fos) are known to be activated by ROS, and lead to the transcription of genes involved in cell growthregulatory pathways and carcinogenesis process, linking the RET receptor signaling to stress response pathways (Klaunig and Kamendulis, 2004; Myers and Mulligan, 2004) . Previous study has shown that NF-kB is constitutively active in C-cell carcinoma and is required for RET-induced transformation (Ludwig et al., 2001) . We have demonstrated respiratory functional defect in MTC patients and cell line associated with mtDNA mutations. The production of ROS is markedly enhanced in many pathological conditions in which the respiratory chain is impaired (Kang and Hamasaki, 2003) . Although RET mutation is likely sufficient to cause C-cell hyperplasia, the precursor lesion to MTC, the high level of ROS resulting from germline mtDNA mutations, especially transversion mutations for FMTC/MEN2, might interact with RET to augment tumour development and/or progression. Kato et al. (2000) have demonstrated that UV-induced free radicals in cells can attack intracellular domains of RET to dimerize the kinase proteins for superactivation. It is known that UV radiation can induce G:C>C:G transversions (Kino and Sugiyama, 2005) , thus providing a circuit of oxidative stress (endogenous sources and exogenous sources)-mtDNA mutation-more ROS production-RET superactivation-tumourigenesis. At present, the cause and effect between mtDNA and RET mutation could not be separated.
The direct consequence of mtDNA mutation in tumourigenesis has been demonstrated by two recent studies (Ishii et al., 2005; Shidara et al., 2005) . One study involved in nuclear gene SDHC located in the mitochondria complex II. A mutation in the SDHC gene resulted in increased oxidative stress, leading to apoptosis and tumourigenesis. The other study demonstrated positive contribution of mtDNA mutation (nt 8993 or 9176) in the ATP synthase subunit 6 gene (ATPase6) to the promotion of cancer by prevention from apoptosis (Shidara et al., 2005) . We identified six mutations (nt 8701, 8768, 8836,8854, 8914, and 9058) in the ATPase6. Four of them are from patients with sporadic MTC and two (nt 8836 and 8914) from MEN2a. The mutations at nt 8836 and 8914 are probably pathogenic, based on interspecies conservation and PolyPhen analysis (Table 2) .
Higher levels of ROS generated in mitochondria are capable of inducing nuclear DNA damage possibly extended to tumour suppressor genes and oncogenes (Hartman et al., 2004) . In addition, a mechanism decreasing oxidative metabolism during normal cell division and growth is expected to direct substrates toward biosyntheses rather than toward complete oxidation to CO 2 . Therefore, any event leading to decreasing oxidative phosphorylations (hypoxia) could provide a proliferating advantage to a transformed or tumour cell in an oxidative tissue (Harris, 2002) . In accordance with this, Simonnet et al. (2002) showed that a low mitochondrial respiratory content correlates with faster tumour growth and aggressiveness in renal-cell carcinoma.
In summary, we have found a high frequency of germline mitochondrial gene mutations in both sporadic and FMTC/MEN2. The distinct mutation patterns (transition vs transversion) between sporadic and FMTC/MEN2 suggest different oxidative stress conditions and repair mechanism defects in the disease process. Mitochondrial respiratory functional analysis of MTC cell line and peripheral lymphocytes from MTC patients with mtDNA mutations revealed a significant defect in mitochondrial respiratory activity. These data suggest that mtDNA mutation may contribute to the MTC development and progression.
